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The mycobacterial PE/PPE proteins have attracted much interest since their formal identiﬁcation just over a decade ago. It has
been widely speculated that these proteins may play a role in evasion of host immune responses, possibly via antigenic variation.
Although a cohesive understanding of their function(s) has yet to be established, emerging data increasingly supports a role for
the PE/PPEproteins at multiple levels of the infectious process. This paper will delineate salient features of the families revealed by
comparative genomics,bioinformaticanalyses and genome-wide screening approaches and will summarise existing knowledge of
subcellular localization, secretion pathways, and protein structure. These characteristics will be considered in light of ﬁndings on
innateandadaptivehostresponsestoPE/PPEproteins,andwewillreviewtheincreasingbody ofdataonBandTcellrecognitionof
these proteins. Finally, we will consider how current knowledge and future explorations may contribute to a more comprehensive
understandingof theseintriguing proteins and their involvementin hostpathogen interactions. Ultimately this informationcould
underpin future intervention strategies, for example, in the area of new and improved diagnostic tools and vaccine candidates.
1.Introduction
Tuberculosis (TB) represents an ongoing threat to global
health, with the current epidemicfuelled by HIV-coinfection
and an increasing incidence of drug resistant strains of
Mycobacterium tuberculosis [1]. Eﬀective new interventions
are urgently needed, and genes that are unique to mycobac-
teria may provide a starting point for developing these.
The intriguing pe/ppe genes ﬁrst attracted attention due
to their genetically hypervariable nature [2, 3]a n dw e r e
initially exploited as informative molecular markers for
mycobacterial strain typing [2, 4]. Shortlythereafter, the ﬁrst
M. tuberculosis genome sequence was completed, and it was
revealed that these variable regions were in fact part of two
extensive families encoding almost 200 putative proteins [5].
It is now known that these genes are unique to mycobacteria
and are particularly abundant in pathogenic mycobacteria,
such as M. tuberculosis. Naturally, the PE/PPE families have
provoked much speculation, although we have yet to estab-
lish a complete understanding of their function. However,
the advent of the mycobacterial genomic age, together with
improved molecular tools and a deeper understanding of the
immunopathogenesis of TB, has advanced our knowledge
of these gene families and the potential functions of their
encoded proteins.
2.PE/PPEGenomics
Analysis of the M. tuberculosis H37Rv genome sequence
revealed the presence of two novel gene families that
comprise almost 10% of the coding capacity of the genome
[5]. These were designated the pe and ppe genes, after
highly conserved Proline-Glutamate and Proline-Proline-
Glutamate residues near the start of their encoded proteins.
The proteins can be categorized into subgroups, encom-
passing members with highly variable length and sequence
features (Figure 1)[ 5]. The relatively conserved N-terminal
is approximately 110 amino acids (aa) and 180 aa in the PE
and PPE families, respectively. The smallest members of both
families consist of just this conserved domain, while other
subclasses haveadditional C-terminal regions. The PE PGRS
(polymorphic GC-rich sequence) and PPE MPTR (major
polymorphic tandem repeat) subgroups possess C-terminal2 Clinical and Developmental Immunology
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Figure 1: Schematic representation of PE and PPE family sub-
groups. PE and PPE proteins possess relatively conserved N-
terminal domains of approximately 110 aa and 180 aa, respectively.
OnesubgroupofthePPEfamilyincorporatesacharacteristic“SVP”
motif at approximately 350 aa. Both PE and PPE families can be
divided into distinct subgroups on the basis of their variable C-
terminal domains. The regions encoded by the Polymorphic GC-
Rich Sequence (PGRS) of the pe family and the Major Polymorphic
Tandem Repeats (MPTR) of the ppe family are major contributors
to genome polymorphism.
regions of enormously variable size—these can reach over
3700 aa in length; they are also the family members which
exhibit the most sequence variation.
The remarkable length and extensive sequence vari-
ation of the PE PGRS and PPE MPTR proteins appear
to be primarily associated with lengthy stretches of GC-
rich, imperfect triplet repeats within their associated genes.
These are thought to be hotspots for recombination events
and other mutations, including insertion of transposable
elements [5, 6]. Other pe/ppe-associated sequence variation
includes large sequence polymorphisms which appear to be
mediated by highly homologous sequences in the conserved
5  regions of pe/ppe genes [6]. Given the diverse mechanisms
whereby pe/ppe polymorphisms can arise, together with the
high potential for redundancy within the gene families, it
is perhaps unsurprising that some pe/ppe genes vary exten-
sively in clinical isolates [7–9]. Consequently, it has been
speculated that these proteins represent a source of antigenic
variation which allows the organism to escape antigen-
speciﬁc host responses [5, 7, 8]. However, this hypothesis
is as yet unproven, and there is little evidence to support
rapid within-host diversiﬁcation of these genes. Therefore
if the observed sequence variation is providing a source of
antigenic diversity, the beneﬁts of this are likely to operate
on a population-wide scale, rather than within individual
hosts. One study has demonstrated a moderately signiﬁcant
association of large sequence variation in pe pgrs33 with
noncavitary TB and case clustering [10]. However, further
experimentation will be required to establish whether there
is a causal link between these observations, and if so, to
determine the underlying mechanistic basis. It is worth
noting that while the pe pgrs and ppe mptr genes represent
some of the most variable regions of the M. tuberculosis
chromosome, it is an oversimpliﬁcation to extend this to
all pe/ppe family members, as some are in fact conserved
across strains and species [11]. It is important to bear this
distinction in mind when considering potential functional
roles and to extrapolate experimental results with caution.
An increasing wealth of mycobacterial genome sequence
data has advanced our knowledge of the sequence diversity
and evolutionary history of the pe/ppe gene families. One
comparative genomics study revealed that the evolution and
major expansion of the pe/ppe families is closely associated
with the esx regions [12]. These encode the so-called Type
VII or ESX secretion systems, of which there are 5 in M.
tuberculosis [13]. The best characterized of these is ESX-
1, which has been implicated in mycobacterial virulence
through the secretion of eﬀectors such as EsxA and EsxB
[14–16] (otherwise known as ESAT-6 (early secreted anti-
genic target of 6kDa) and CFP-10 (culture ﬁltrate protein
of 10kDa), resp.). Gey van Pittius and colleagues further
showed thatthe most repetitive and variablefamily members
represented by the PE PGRS and PPE MPTR subgroups
are also the most phylogenetically recent. These subgroups
are restricted to the pathogenic mycobacteria, and their
massiveexpansioniscloselyassociatedwiththemostrecently
duplicated esx gene cluster, esx-5 [12]. These ﬁndings were
suggestive of a functional link between the PE/PPE families
and the ESX secretion systems. Indeed, it has since been
demonstrated that the secretion of multiple PE/PPE family
members is ESX-mediated [17–19].
3.Transcriptomics,Proteomics,
Structure,and SubcellularLocation
In tandem with burgeoning mycobacterial genome data,
other “-omics” undertakings have shed light on certain
aspects of the PE/PPE families. An exhaustive account of
pe/ppe transcriptomics is beyond the scope of this paper.
However, it is worth mentioning that a study of M. tuber-
culosis pe/ppe gene expression under 15 diﬀerent conditions
revealed that 128/169 pe/ppe genes analysed were diﬀer-
entially regulated [20]. Other groups have demonstrated
that several pe/ppe genes are upregulated upon macrophage
infection and in host tissues [21–24]. For example, Rachman
et al. demonstrated that two pe genes (pe11, pe34), four
pe pgrs (pe pgrs14, 33, 55 and 57), and three ppe-mptr
genes (pe pgrs54, 55 and 62) were all upregulated in human
lung granulomas compared to in vitro grown bacteria [24].
Together with other published expression data, these results
lend support to the idea that the pe/ppe genes play important
functional roles in vivo.
Characterisation of regulatory and other mutants has
revealed that subsets of pe/ppe genes are frequently among
the genes whose expression levels are altered [25–27]. In
one example, disruption of the virulence-associated PhoPR
two-component regulator resulted in altered expression of
at least 14 pe/ppe genes. These include pe pgrs41,w h i c h
demonstrated a striking 143-fold higher expression level inClinical and Developmental Immunology 3
wild type M. tuberculosis compared to the phoP mutant [26].
It has been demonstrated that selected pe/ppe genes may
be diﬀerentially regulated in genotypically diverse clinical
isolates [28–30]. For instance, Gao et al. examined gene
expression in 10 clinical isolates of M. tuberculosis and found
that 28 of the 77 pe/ppe genes included in the analysis
showed variable expression [29]. There is also evidence
for divergent regulation of speciﬁc family members within
individual strains [31, 32]. This is exempliﬁed by pe pgrs16
and pe pgrs26, which are thought to be inversely regulated in
vitro [31], although the mechanistic basis for this apparently
coordinated expression is unclear. Taken together, available
data does not support global regulation of pe/ppe gene
expression, suggesting that there is likely to be a relatively
high degree of plasticity in the pe/ppe expression repertoire.
Although this may suggest that some pe/ppe genes are
not required at all, this could also indicate that members
within diﬀerent subgroups of the family play subtly diﬀerent
functionalrolesandarerequiredatdiﬀerentstagesofdisease.
The existence of multiple highly similar pe/ppe family
memberssuggestsahighpotentialforfunctionalredundancy
within subgroups. It is therefore not surprising that very
few of these genes are essential for in vitro or in vivo
growth, as demonstrated in a series of studies by Rubin and
colleagues [33–35], Table S1 (see Table S1 in supplementary
material available online at doi:10.1155/2011/497203). This
high degree of redundancy contributes to one of the
experimental challenges presented by this family, that is,
that mutations in single pe/ppe genes may lack measurable
phenotypes. However, there are some examples where this
is not the case, and analysis of selected pe/ppe mutants has
yielded important functional insights, as will be described
below.
High-throughput proteomics-based studies have high-
lighted further challenges of working with PE/PPE proteins.
The proteins are often very large, may be tightly associated
with the cell wall, and can have limited proteolytic cleavage
sites. These inherent properties may restrict the utility
of some high-throughput proteomics approaches [18].
Nonetheless, using optimized growth conditions and sample
preparation methods in conjunction with sensitive detection
methodologies, some studies have successfully identiﬁed the
subcellular localization of selected PE/PPE proteins in diﬀer-
ent mycobacterial strains and species (Table S1). For exam-
ple, using proteolytic shaving of intact Mycobacterium avium
subsp. paratuberculosis followed by LC-MS/MS, Newton et
al. identiﬁed 2 PPE orthologues associated with the cell wall
[36]. PE PGRS and PPE orthologues were also identiﬁed in
thecell membrane fractionof Mycobacterium immunogenum
[37], and a recent detailed analysis of the Mycobacterium
marinum capsule using cryoelectron microscopy in con-
junction with LC-MS/MS demonstrated that 6/25 major
cell surface proteins were members of the PE/PPE families
[38]. Similarly, M˚ alen et al. utilized MALDI-MS and LC-
MS/MS to identify at least 7 and 16 PE/PPEs in the M. tuber-
culosis culture ﬁltrate and envelope fractions, respectively
[39, 40]. High-throughput proteomics approaches therefore
suggest that cell wall/surface localization is a characteristic
of several PE/PPE proteins. This has been corroborated
by more focused studies which provide further substantial
evidence indicating that numerous PE/PPE family members
are associated with the bacterial cell wall [37, 38, 40–43].
These include PPE36 [42], PPE68 [41], PE PGRS33 [44],
PE PGRS63 [43], and PPE MPTR34, with further examples
listed in Table S1. In some cases, results indicate surface
exposure of these proteins [17, 44–47]. Although it has been
proposed that PE/PPE proteins could form complex surface
structures [48], this hypothesis has yet to be addressed
experimentally.
To date, only one PE/PPE protein structure has been
solved, perhaps reﬂecting the diﬃculty experienced with
recovering stable, soluble recombinant PE/PPE proteins.
Strategies used to successfully overcome this challenge
include on-column refolding [49], use of mycobacterial host
strains for expression [50], and coexpression of cognate
PE/PPE pairs [51, 52]. Using the latter approach, Strong and
coworkers successfully puriﬁed recombinant PE25/PPE41
and subsequently determined the crystal structure, which
showed that the protein pair forms a stable 1:1 het-
erodimer [52]. The PE/PPE complex is reminiscent of the
EsxA/EsxB complex, which could suggest common secretion
pathways. Intriguingly, the PE25/PPE41 complex displays
an apolar stripe on one face, which could represent a
dockingsite for an as-yet unidentiﬁed bacterial or host target
[52]. An attempted structure/function analysis revealed
that the heterodimeric complex shares some features of
signal transduction molecules [52], although this has yet
to be explored experimentally. It is unknown whether the
PE25/PPE41 structure is truly representative of the rest of
the protein family. Indeed, it is unlikely that this structure
can be extrapolated to family members which are not
predicted to form heterodimers [53]o rw h i c hd e m o n s t r a t e
substantial variation in sequence length and content. The
structural biology of PE/PPE proteins is therefore an area
in much need of further development, as characterization
and comparative analysis of additional PE/PPE structures
could perhaps provide clues to their possible function.
Anothercrucialstep towardsdetermining the functionofthe
PE/PPE proteins will be identifying their interaction part-
ners. In particular, determining host targets of these proteins
could provide critical insights into their impact on host
responses.
As mentioned above, the PE/PPE proteins are intimately
associated with the ESX systems [12]. A functional link has
been elucidated by the work of Abdallah and colleagues,
who demonstrated that the ESX-5 apparatus mediates the
secretion of multiple PE/PPE proteins, including members
of the PE PGRS and PPE MPTR subsets [17, 18]. The ESX-
5 locus is implicated in M. marinum virulence [17, 54],
although it remains to be seen whether the secreted PE/PPE
proteins play a central role in this. In addition, ESX-5-
mediated PE/PPE secretion has yet to be demonstrated
for M. tuberculosis. Of course, given the parallels with
the EsxA/EsxB complex and the close association with the
ESX secretion apparatus, it is tempting to speculate that
PE/PPE complexes (or the individual constituent proteins)
could be virulence eﬀectors secreted by ESX-5. Once again,
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to other family members; it is worth noting that some
PE/PPE proteins in fact possess functional N-terminal signal
peptide cleavage sites [39]. It is therefore plausible that their
secretion/localization may occur via other mechanisms, for
example, the Sec-dependent export pathway. In support of
this, several studies have reported cell-wall localization of
PE/PPE proteins in Mycobacterium smegmatis, which lacks
the ESX-5 region [44, 46, 47, 55]. In addition to the possible
role of ESX-5, there is some evidence implicating ESX-
1 in PE/PPE secretion. For example, the genes encoding
PE35/PPE68 are situated within the esx-1 region, and one
study has suggested that PE35 secretion is ESX-1-dependent
[19]. Others have demonstrated cell-wall association of
PPE68 in M. tuberculosis [40, 41], and this protein also
interacts with multiple components of the ESX-1 machinery
[56, 57]. Interestingly, disruption of ppe68 is associated with
increased secretion of ESAT-6, leading to the suggestion that
PPE68mayactas an ESX-1gating protein[58],althoughthis
has yet to be experimentally veriﬁed.
Regardless of their secretion mechanism, several lines
of evidence support surface localization of PE/PPE proteins
(Table S1). Some PE/PPEs may be actively secreted or
passively shed from the bacterium into the host cell milieu,
and couldevenbe released from host cells via exosomes [59].
Thus, they are ideally positioned to interact with the host
immune system. Indeed, there is extensive evidencethat they
dosoinwaysthatcouldhaveimportantconsequencesforthe
outcome of infection.
4.PE/PPEsModulateInnate
Immune Responses
There is mounting evidence that PE/PPE proteins interact
with host components and thereby modulate and possibly
subvert critical innate immune pathways. Ramakrishnan
et al. provided the ﬁrst deﬁnitive evidence that (at least
some) PE PGRS proteins are virulence factors, when they
showed thattwoM.marinum pe pgrs geneswere requiredfor
survival in macrophages and granulomas [60]. Since then,
the most extensively studied “examplar” member of the M.
tuberculosis PE PGRS family, namely PE PGRS33, has pro-
vided some insight into the numerous ways in which these
proteins could modulate host immune responses. Detailed
examination revealedthatPE PGRS33interactsdirectly with
TLR-2, thereby mediating apoptosis and cytokine secretion
[61]. Others have conﬁrmed that PE PGRS33 promotes host
cell apoptosis [59], and, in one study, necrosis [62]. Interest-
ingly, sequence variants of PE PGRS33 and other PE PGRS
family members elicited diﬀerential eﬀects [61]. PE PGRS11
and PE PGRS17 were also shown to interact with TLR-2,
prompting maturation and activation of dendritic cells [63].
Independent studies have subsequently shown that PPE18
and an MPTR-containing domain of PPE MPTR34 can also
modulate host responses through TLR-2 [64, 65]. Although
it has yet to be established if TLR-2 engagement is a common
property of PE/PPE proteins, these results suggest that the
additive host response to interaction with multiple PE/PPE
proteins may be very complex, and could profoundly impact
on the course of disease.
PE/PPEproteins canalso inﬂuence macrophage function
by other means. For example a BCG pe pgrs33 transposon
mutant demonstrated reduced entry into macrophages [66],
suggesting that PE PGRS33 may play a role in promoting
macrophage uptake. In contrast to other bacteria, this
may be advantageous for M. tuberculosis at the very early
stage of infection, as it could promote dissemination and
colonizationofmultipleorgans.Thisstrategyisonlyeﬀective
because the pathogen has evolved multiple strategies to
overcome the hostile environment encountered within host
cells. In this context, several PE/PPE proteins have been
shown to facilitate, or be required for, in vivo survival
[35, 60, 67, 68]. A key macrophage defence mechanism is
phagosome maturation and acidiﬁcation, which normally
results in killing of intraphagosomal pathogens. However,
M. tuberculosis is adept at subverting this pathway, and
t h e r ei se v i d e n c et h a td i ﬀerent PE/PPE family members may
contribute to this. Selected PE/PPE family members have
been implicated in the modulation of vacuole acidiﬁcation
[69–71]. For example, a high-throughput analysis of a
Mycobacterium bovis BCG tranposon mutant library iden-
tiﬁed four pe pgrs mutants (pe pgrs5, 28, 44, 59)a n dt h r e e
ppe mptr mutants (ppe mptr10, 16, 21) that were enriched
in acidiﬁed phagosomes. A more recent study showed that a
M. tuberculosis ppe54 transposon mutant was impaired in its
abilitytoarrestphagosomematurationandtraﬃckedrapidly
into acidiﬁed compartments [72].
Available data therefore indicates that selected PE/PPE
family members play important roles in subverting innate
immune responses, and together with other bacterial media-
tors, may assist the pathogen in establishing itself within the
host. Once this has occurred, PE/PPEs may then contribute
to processes which allow the pathogen to persist within
host tissues. Intriguingly, enzymatic functions have been
assigned to 3 PE proteins: PE PGRS11 has been reported to
be a functional phosphoglycerate mutase [55], while both
PE PGRS63 (LipY, [43]) and PE11 (LipX, [73]) demonstrate
lipase activity. The latter 2 proteins may therefore play a role
in energy provision. It should be noted though that these are
exceptional examples; they appear to have arisen as a result
ofrecombination eventswhich leadto functional divergence,
and enzymatic activityis notpredicted tobe ageneralfeature
of the PE/PPE proteins.
Once established within their intracellular niche, there
are a number of ways in which mycobacteria can limit
engagement of the adaptive immune response, and the
PE/PPE proteins may contribute to some of these mecha-
nisms. The observation that PE PGRS proteins bear some
resemblance to the Epstein-Barr virus nuclear antigen
( E B V N A )g a v er i s et os p e c u l a t i o nt h a t ,a k i nt ot h eE B V N A ,
the PE PGRS proteins may inhibit antigen processing [5].
This has subsequently been demonstrated for PE PGRS33
[48]a n dP EPGRS17 [74], supporting the idea that these
proteins may assist in immune evasion by limiting antigen
presentation, thereby preventing recognition and killing of
mycobacteria-infected host cells.
Taken together, the observations described above suggest
thatdiﬀerentPE/PPEproteinsmayplaydistinct,butcomple-
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to facilitate adaptation to the hostile host environment.
Members of these families may be critical mediators of
host responses which ultimately determine the outcome of
infection. Understanding their individual and cumulative
impact on host responses is an important undertaking which
could provide the starting point for novel interventions.
The large number and diverse eﬀects of these proteins
present some experimental challenges. Future explorations
may therefore beneﬁt from systems-level approaches to help
unravel their biological role.
5.Band T CellRecognitionof
PE/PPEProteins
5.1. Humoral Immunity. The contribution of humoral re-
sponsestocontrolling M.tuberculosis infection haslongbeen
underappreciated. However, it is known that mycobacteria-
speciﬁc antibodies can both inﬂuence mycobacterial dissem-
ination and modulate potentially detrimental inﬂammatory
tissue responses [75, 76]. It is increasingly recognized that
B cells can exert an inﬂuence on T cells [77, 78]a n da r ea n
importantconstituentofgranulomaarchitecture[79].Bcells
are thus likely to be more important in determining the out-
come of infection with M. tuberculosis than previously sup-
posed, and ignoring this aspect of the host immune response
may restrict our understanding of TB immunopathology. In
this context, PE/PPE family members are a potentially rich
source of B cell epitopes, and a number of PE/PPE proteins
may be surface exposed, increasing the likelihood that they
could be targeted by the humoral response. Accordingly,
numerous PE/PPE proteins have been shown to elicit B cell
responses (Table S1). There is evidence for both members of
the PE PGRS and PPE MPTR families that the highly repet-
itive domains are chieﬂy responsible for eliciting antibody
responses. Deloguand Brennan were the ﬁrst todemonstrate
diﬀerential B and T cell targeting of the conserved N-
terminal and highly repetitive, more variable, C-terminal
of PE PGRS33; DNA vaccination of mice with only the
PE domain elicited predominantly cell-mediated immunity
and subsequent protection against challenge, whereas a full-
length PE PGRS33 construct promoted a nonprotective, B
cell-skewed response [80]. In agreement with these results,
PPE MPTR42 was found to elicit a primarily humoral
response, directed toward the glycine and asparagine-rich
repeat domain [81]. In other work, it was shown that the
full-length PE PGRS17 and PE PGRS62 proteins were pref-
erentially recognized in comparison to the PE-only versions
[82]. Further elucidation of diﬀerential immune targeting
of PE/PPE proteins could enable ﬁne-tuning of new vaccine
candidates.
5.2. PE/PPE Proteins as T Cell Immunogens. Cell-mediated
immunity is especially important in the control of M.
tuberculosis infection [83, 84]. Therefore, T cell antigens are
of great interest for vaccine development and could form
useful components of subunit DNA or protein vaccines
or engineered into live recombinant vectors. Consequently,
numerous studies have investigated the ability of PE/PPE
proteins to elicit T cell responses (Table S1). For example, T
cell expression cloning was successfully exploited to identify
T cell immunogens in M. tuberculosis-sensitized individuals
[85];thisrelatively high-throughputapproach resultedinthe
identiﬁcation of the potent T cell antigen Mtb39a, which is
encoded by Rv1196/ppe18. In subsequent work, this antigen
has been evaluated aspart of the polyproteinsubunit vaccine
candidate, Mtb72f, as described further below (Section 6.2).
In addition to PPE18, at least 20 PE/PPE proteins have
been reported to elicit CD4 and/or CD8 responses, either
in the form of whole recombinant proteins or as individual
peptides (Table S1). Together, these results suggest that
PE/PPE proteins are worthy of further evaluation as poten-
tially protective antigens for inclusion in new TB vaccine
candidates.
Asidefrom the possible practicalapplicationsof PE/PPE-
derived antigens (see Section 6), their high degree of
immunogenicity could also provide some clues regarding
their biological function. A recent study which combined
multiple genome sequence comparisons with analysis of
published immunogenicity data reported an unexpectedly
high level of conservation of human T cell epitopes [86].
This runs counter to the existing dogma that antigenic
targets will exhibit a relatively high degree of variation due
to selection pressures imposed by host immune responses.
Unfortunately, the high-throughput sequencing methodol-
ogy used in the study imposes inherent technical limitations,
which impact substantially on pe/ppe genes; due to the short
sequence reads, highly repetitive, multicopy sequences are
diﬃcult to accurately assemble. As a result, PE/PPE proteins
were excluded from their analysis. It is possible that some
members of these protein families, in particular within the
PE PGRS and PPE MPTR subgroups, could be exceptions
to the described ﬁnding. However, our own recent work
suggests that a large subset of the PE/PPE family, which is
relatively well conserved across multiple clinical isolates, is
also highly immunogenic (manuscript in preparation). The
most conserved regions of the proteins are also the most well
recognized, and even when PE/PPE amino acid sequences
do vary, this does not necessarily impair epitope recognition
by cross-reactive T cells (manuscript in preparation). Taken
together, this suggests that at least some PE/PPE family
members will ﬁt the paradigm revealed by Comas et al. [86].
Thisraises thequestionofwhetherthehighlevelofimmuno-
genicity displayed by proteins such as the PE/PPEs confers a
selective advantage on the pathogen. As speculated by others
[87], it is possible that robust inﬂammatory responses lead
to lung damage which could promote M. tuberculosis trans-
mission. An alternative hypothesis is that these potent T cell
antigens could provide a further means of immune evasion
by overwhelming and misdirecting the adaptive immune
response.
To date, there is little experimental data to support the
contention that PE/PPE proteins contribute to antigenic
variation in the conventional understanding of the phe-
nomenon. However, there is substantial evidence that these
proteins contribute to immune evasion via other important
mechanisms, as described above.6 Clinical and Developmental Immunology
6.TranslationalApplications
The ﬁndings described in the preceding sections have impli-
cations for both vaccine developmentand diagnostic tools.
6.1. Diagnostic Tools. In terms of new diagnostic tools,
several highly immunogenic PE/PPEs have been identiﬁed,
which could contribute to the development of antigen
cocktails to be used in IFN-γ release assays or antibody-
based tests. However, there are some caveats. Firstly, there
is the issue of intraspecies cross-reactivity—a number of
PE/PPE proteins are present in mycobacteria outside of the
M. tuberculosis complex [12] and are recognised immune
targets [36, 81, 88, 89]. Therefore, antigens would need to be
rigorously evaluated to ensure species-speciﬁcity. Secondly,
although there are some indications that some PE/PPE-
derived antigens may distinguish between vaccinated and
nonvaccinated individuals, or between diﬀerent forms of
disease and/or stages of infection, [55, 82, 90–95], existing
data suggests that diﬀerential diagnostic capability does not
applytoallPE/PPEproteins [90,91,96].Thereforetheirutil-
ity in distinguishing between active disease, latent infection
and vaccinated individuals will likely be limited to selected
family members, and would need rigorous validation in
larger patient cohorts prior to clinical implementation.
6.2. Vaccines. PE/PPE proteins are a potentially rich source
of T-cell antigens, and several of these have been assessed
for possible inclusion in new vaccines [80, 97–102], Table
S1. As mentioned above, the PPE18-based subunit vaccine
candidate Mtb72f, formulated with the adjuvant AS02A, has
yielded promising results in multiple animal models [103,
104] and is now undergoing Phase I clinical trials [105, 106].
Similarly, evaluation of 2 polyprotein vaccine candidates
which incorporate PPE MPTR42 is at a relatively advanced
stage. PPE MPTR42 was shown to confer partial protection
in mice when formulated with the TLR-9 agonist CpG
[97]. The fusion protein ID83 (which incorporates Rv1813,
Rv3620, and PPE MPTR42) elicits protective immunity in
mice [97], which can be modulated by use of diﬀerent
adjuvants and/or route of immunization [107]. In recent
work, a similar fusion protein (ID93, which incorporates
PPE MPTR42, Rv1813, Rv3620 as well as a fourth antigen,
Rv3619)hasbeenshowntoelicitprotectionagainstchallenge
with virulent M. tuberculosis in both mice and guinea pigs
[108]. As it is likely that subunit vaccine candidates (either
DNA or protein-based) will be introduced in the context
of a BCG-prime/subunit boost regimen, it is appropriate
that these be tested in this setting; importantly, ID93 oﬀers
enhanced protection in a BCG-prime/ID93-boost regimen
in guinea pigs [108]. Furthermore, ID93 is immunogenic in
cynomolgous macaques and elicits polyfunctional CD4 and
CD8 responses in peripheral blood mononuclear cells from
BCG-vaccinated humans [108]. Together, these promising
preclinical results support further evaluation of ID93 in
humans in Phase I clinical trials.
The protective capacity of additional PE/PPE-derived
subunit candidates is also under investigation. For example,
DNA vaccines based on PPE44 [99], PPE41 [100], and
the PE domain of PE PGRS33 [80] have all been shown
to elicit protection in mice. In addition, PE PGRS62- and
PE20-derived DNA vaccines have been shown to reduce
guinea pig bacterial lung burden by >0.5 log [101]. An
alternative to the BCG prime/subunit boost approach is to
heterologously express candidate antigens in a live vaccine
vehicle, and thereby appropriately supplement/modulate
immune responses. Wang et al. have explored this approach
by coexpressing PPE57 and Ag85B in BCG and have demon-
strated that the recombinant BCG strain elicits enhanced
immunogenicity in mice [102]. However, it has yet to be
determined whether this approach will result in improved
protection.
In addition to their immunogenicity, other features of
PE/PPE proteins may be beneﬁcial to vaccine development
eﬀorts. For example, the PE domain is thought to be respon-
sible for protein localization to the cell wall [44], and this
property could be exploited to ensure optimal localization
of PE/PPE-derived or other heterelogous antigens in live
recombinant vaccines. Secondly, selected PE/PPE proteins
may be potent immune-modulators that could be exploited
to ﬁne-tune the immune response to enhance protective
capabilities of vaccine antigens.
Although PE/PPE proteins show potential for exploita-
tion in vaccine development eﬀorts, several issues need
to be considered. Firstly, many of the known PE/PPE
immunogens havebeen identiﬁed on thebasis of their ability
to stimulate IFN-γ production. While this cytokine is clearly
important for the control of TB, it is not necessarily the best
predictor of protection against subsequent challenge [109].
The simultaneous production of other cytokines, such as
IL-2, has been shown to be a signiﬁcant component of a
protective immune response [110]. Likewise, the phenotypic
makeup of the responding cell population is also important;
forexample, thepresenceofantigen-speciﬁc centralmemory
T cells correlates with protection [111]. Future antigen
discovery and evaluationexercises therefore need to consider
a broader cytokine proﬁle, as well as the phenotype of the
responding cell populations. A second point of caution
is that the many of the immunogenic PE/PPE epitopes
which have been identiﬁed are recognized during active
infection, suggesting that the ability to mount an immune
response againstthemdoesnotnecessarily conferprotection.
However, with a more comprehensive understanding of
what constitutes a protective immune response, it may
be possible to ﬁne-tune factors such as vaccination dose,
timing, and formulation to accordingly modulate responses
to vaccination. Finally, it will also be important to have
a clearer understanding of PE/PPE function and possible
adverse eﬀects on host responses. For example, at least
3P EPGRS proteins, PPE MPTR34, and PPE18 have all
been shown to interact directly with surface receptors on
host macrophages eliciting responses such as apoptosis and
cytokine production [61, 63–65] that may not necessarily be
desirable outcomes. Until we have a better understanding
of the nuances of PE/PPE-host interactions, the use of
these proteins as vaccine candidates should be cautiously
approached.Clinical and Developmental Immunology 7
Importantly, consideration is increasingly being given to
the “real-world” setting in which new TB vaccine candidates
will be tested and utilized. For example, epitope prediction
tools can be used to assess the prevalence of peptides which
are likely to bind MHC alleles found in the target population
[112]. Also, multiple genome sequence comparisons can
help to determine the degree of conservation of predicted
MHC binding peptides in circulating mycobacterial strains
[113]. Using Mtb72f as an example, McNamara et al. applied
a combination of epitope prediction software packages to
demonstrate that several MHC DRB1 alleles would have
limited binding topredicted PPE18 epitopes [114].They fur-
ther showed that predicted binding peptides were relatively
unconserved [114], in accordance with an earlier report
[113]. On the basis of these results, it was suggested that
Mtb72f might have limited eﬃcacy in selected populations
[114]. Although epitope prediction tools are still in need of
reﬁnement, in silico approaches such as these can be applied
to prioritize antigen screening. They could also be used to
predict the likely eﬃcacy of selected vaccine candidates prior
to undertaking lengthy and resource-intensive clinical trials.
7.Conclusions
More than a decade after their discovery, a cohesive under-
standing of the function of the PE/PPE proteins remains
elusive. The large and complex families pose a number of
experimental challenges. However, some interesting themes
are emerging: several members of the family trigger a range
of innate immune responses, and many are targets of the
adaptiveimmunesystem.Thesefamiliesareapotentiallyrich
source of diagnostic and vaccine antigens and could even
ﬁnd application as immunomodulatory agents. However,
it will be critical to improve our understanding of their
function and potential eﬀects of these proteins on the host.
Fundamental areas in need of attention include PE/PPE
structural biology, identiﬁcation of PE/PPE host targets, and
bacterial interaction partners and an expanded understand-
ing of the mechanisms whereby these proteins modulate
hostimmuneresponses.Someoftheexperimentalchallenges
posed by these large and complex proteins families could be
addressed using approaches informed by the ﬁeld of systems
biology. Future investigations which exploit the wealth of
mycobacterial genome sequence data in the context of our
increasing understanding of host and pathogen biology may
provide a platform for answering some of the intriguing
questions surrounding these enigmatic proteins.
Acknowledgment
S. Sampson is funded by the Wellcome Trust.
References
[1] C. Dye and B. G. Williams, “The population dynamics and
control of tuberculosis,” Science, vol. 328, no. 5980, pp. 856–
861, 2010.
[ 2 ]P .W .M .H e r m a n s ,D .V a nS o o l i n g e n ,a n dJ .D .A .V a n
Embden, “Characterization of a major polymorphic tandem
repeat in Mycobacterium tuberculosis and its potential use in
the epidemiology of Mycobacterium kansasii and Mycobac-
terium gordonae,” Journal of Bacteriology, vol.174, no. 12, pp.
4157–4165, 1992.
[3] S. Poulet and S. T. Cole, “Characterization of the highly
abundant polymorphic GC-rich-repetitive sequence (PGRS)
present in Mycobacterium tuberculosis,” Archives of Microbiol-
ogy, vol. 163, no. 2, pp. 87–95, 1995.
[4] R. Warren, M. Richardson, S. Sampson et al., “Genotyp-
ing of Mycobacterium tuberculosis with additional markers
enhances accuracy in epidemiological studies,” Journal of
Clinical Microbiology, vol. 34, no. 9, pp. 2219–2224, 1996.
[ 5 ]S .T .C o l e ,R .B r o s c h ,J .P a r k h i l le ta l . ,“ D e c i p h e r i n gt h e
biology of Mycobacterium tuberculosis from the complete
genome sequence,” Nature, vol. 393, no. 6685, pp. 537–544,
1998.
[ 6 ]C .R .M c E v o y ,P .D .V a nH e l d e n ,R .M .W a r r e n ,a n dN .C .G .
VanPittius, “Evidence fora rapid rateof molecularevolution
atthehypervariableandimmunogenicMycobacterium tuber-
culosis PPE38gene region,” BMC Evolutionary Biology,v o l .9 ,
no. 1, article 237, 2009.
[ 7 ]A .K a r b o u l ,A .M a z z a ,N .C .G e yV a nP i t t i u s ,J .L .H o ,
R. Brousseau, and H. Mardassi, “Frequent homologous
recombination events in Mycobacterium tuberculosis PE/PPE
multigene families: potential role in antigenic variability,”
Journal of Bacteriology, vol.190, no.23, pp. 7838–7846,2008.
[ 8 ]S .T a l a r i c o ,M .D .C a v e ,C .F .M a r r s ,B .F o x m a n ,L .Z h a n g ,
and Z. Yang, “Variation of the Mycobacterium tuberculosis
PE PGRS33 gene among clinical isolates,” Journal of Clinical
Microbiology, vol. 43, no. 10, pp. 4954–4960, 2005.
[9] S. Talarico, L. Zhang, C. F. Marrs et al., “Mycobacterium
tuberculosis PE PGRS16 and PE PGRS26 genetic polymor-
phismamongclinicalisolates,”Tuberculosis,vol.88,no.4,pp.
283–294, 2008.
[10] S.Talarico,M.DonaldCave,B.Foxmanet al.,“Associationof
Mycobacterium tuberculosis PE PGRS33 polymorphism with
clinical and epidemiological characteristics,” Tuberculosis,
vol. 87, no. 4, pp. 338–346, 2007.
[11] A. Cubillos-Ruiz, J.Morales,andM. M.Zambrano,“Analysis
of the genetic variation in Mycobacterium tuberculosis strains
by multiplegenomealignments,”BMCResearch Notes,v ol.1,
article 110, 2008.
[12] N.C.GeyV anPittius,S.L.Sampson,H.Lee,Y .Kim,P .D .van
Helden, and R. M. Warren, “Evolution and expansion of the
Mycobacterium tuberculosis PE and PPE multigene families
and their association with the duplication of the ESAT-6
(esx) gene cluster regions,” BMC Evolutionary Biology,v o l .6 ,
article 95, 2006.
[13] N. C. Gey Van Pittius, J. Gamieldien, W. Hide, G. D.
Brown, R. J. Siezen, and A. D. Beyers, “The ESAT-6 gene
cluster of Mycobacterium tuberculosis and other high G+C
Gram-positive bacteria,” Genome Biology,v o l .2 ,n o .1 0 ,p .
RESEARCH0044, 2001.
[14] A. S. Pym, P. Brodin, R. Brosch, M. Huerre, and S. T.
Cole, “Loss of RD1 contributed to the attenuation of the
live tuberculosis vaccines Mycobacterium bovis BCG and
Mycobacterium microti,”Molecular Microbiology,v ol.46,no .
3, pp. 709–717, 2002.
[15] T. Hsu, S. M. Hingley-Wilson, B. Chen et al., “The primary
mechanism of attenuation of bacillus Calmette-Gu´ erin is a
loss of secreted lytic function required for invasion of lung
interstitial tissue,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 100, no. 21, pp.
12420–12425, 2003.8 Clinical and Developmental Immunology
[ 1 6 ]S .A .S t a n l e y ,S .R a g h a v a n ,W .W .H w a n g ,a n dJ .S .C o x ,
“Acute infection and macrophage subversion by Mycobac-
terium tuberculosis require a specialized secretion system,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 100, no. 22, pp. 13001–13006, 2003.
[17] A. M. Abdallah, T. Verboom, F. Hannes et al., “A speciﬁc
secretion system mediates PPE41 transport in pathogenic
mycobacteria,” Molecular Microbiology,v o l .6 2 ,n o .3 ,p p .
667–679, 2006.
[18] A. M. Abdallah, T. Verboom, E. M. Weerdenburg et al.,
“PPE and PE-PGRS proteins of Mycobacterium marinum
are transported via the type VII secretion system ESX-5,”
Molecular Microbiology, vol. 73, no. 3, pp. 329–340, 2009.
[19] S. M. Fortune, A. Jaeger, D. A. Sarracino et al., “Mutually
dependent secretion of proteins required for mycobacterial
virulence,” Proceedings of the National Academy of Sciences
of the United States of America, vol. 102, no. 30, pp. 10676–
10681, 2005.
[20] M. I. Voskuil, D. Schnappinger, R. Rutherford, Y. Liu, and G.
K. Schoolnik, “Regulation of the Mycobacterium tuberculosis
PE/PPE genes,” Tuberculosis, vol. 84, no. 3-4, pp. 256–262,
2004.
[ 2 1 ]G .C a p p e l l i ,E .V o l p e ,M .G r a s s i ,B .L i s e o ,V .C o l i z z i ,a n d
F. Mariani, “Proﬁling of Mycobacterium tuberculosis gene
expression during human macrophage infection: upregu-
lation of the alternative sigma factor G, a group of tran-
scriptionalregulators,andproteins with unknownfunction,”
Research in Microbiology, vol. 157, no. 5, pp. 445–455, 2006.
[22] P. Font´ a n ,V .A r i s ,S .G h a n n y ,P .S o t e r o p o u l o s ,a n dI .S m i t h ,
“Global transcriptional proﬁle of Mycobacterium tuberculosis
during THP-1 human macrophage infection,” Infection and
Immunity, vol. 76, no. 2, pp. 717–725, 2008.
[ 2 3 ]A .H .L i ,S .J .W a d d e l l ,J .H i n d se ta l . ,“ C o n t r a s t i n g
transcriptional responses of a virulent and an attenuated
strain of Mycobacterium tuberculosis infecting macrophages,”
PloS one, vol. 5, no. 6, Article ID e11066, 2010.
[24] H. Rachman, M. Strong, T. Ulrichs et al., “Unique transcrip-
tome signature of Mycobacterium tuberculosis in pulmonary
tuberculosis,” Infection and Immunity,v o l .7 4 ,n o .2 ,p p .
1233–1242, 2006.
[25] A. J. Vallecillo and C. Espitia, “Expression of Mycobacterium
tuberculosis pe pgrs33 is repressed during stationary phase
and stress conditions, and its transcription is mediated by
sigma factor A,” Microbial Pathogenesis,v o l .4 6 ,n o .3 ,p p .
119–127, 2009.
[ 2 6 ]S .B .W a l t e r s ,E .D u b n a u ,I .K o l e s n i k o v a ,F .L a v a l ,M .D a ﬀe,
and I. Smith, “The Mycobacterium tuberculosis PhoPR two-
componentsystemregulates genes essentialforvirulence and
complex lipid biosynthesis,” Molecular Microbiology,v o l .6 0 ,
no. 2, pp. 312–330, 2006.
[27] R. M. Goldstone, S. D. Goonesekera, B. R. Bloom, and S. L.
Sampson, “The transcriptional regulator Rv0485 modulates
the expression of a pe and ppe gene pair and is required
for Mycobacterium tuberculosis virulence,” Infection and
Immunity, vol. 77, no. 10, pp. 4654–4667, 2009.
[28] G. Delogu, M. Sanguinetti, C. Pusceddu et al., “PE PGRS
proteins are diﬀerentially expressed by Mycobacterium tuber-
culosis in host tissues,” Microbes and Infection,v o l .8 ,n o .8 ,
pp. 2061–2067, 2006.
[29] Q.Gao,K.E.Kripke,A.J.Saldanha,W.Yan,S.Holmes,andP.
M. Small, “Gene expression diversity among Mycobacterium
tuberculosis clinical isolates,” Microbiology, vol. 151, part 1,
pp. 5–14, 2005.
[30] L. Rindi, I. Peroni, N. Lari, D. Bonanni, E. Tortoli, and
C. Garzelli, “Variation of the expression of Mycobacterium
tuberculosis ppe44 gene among clinical isolates,” FEMS
Immunology and Medical Microbiology, vol. 51, no. 2, pp.
381–387, 2007.
[31] V. Dheenadhayalan, G. Delogu, M. Sanguinetti, G. Fadda,
and M. J. Brennan, “Variable expression patterns of
Mycobacterium tuberculosis PE PGRS genes: evidence that
PE PGRS16 and PE PGRS26 are inversely regulated in vivo,”
Journal of Bacteriology, vol.188, no.10, pp. 3721–3725,2006.
[32] J. Flores and C. Espitia, “Diﬀerential expression of PE and
PE PGRS genes in Mycobacterium tuberculosis strains,”Gene,
vol. 318, no. 1-2, pp. 75–81, 2003.
[ 3 3 ] C .M .S a s s e t t i ,D .H .B o y d ,a n dE .J .R u b i n ,“ G e n e s
required for mycobacterial growth deﬁned by high density
mutagenesis,” Molecular Microbiology, vol. 48, no. 1, pp. 77–
84, 2003.
[34] C. M. Sassetti and E. J. Rubin, “Genetic requirements for
m y c o b a c t e r i a ls u r v i v a ld u r i n gi n f e c t i o n , ”Proceedings of the
National Academy of Sciences of the United States of America,
vol. 100, no. 22, pp. 12989–12994, 2003.
[35] J. Rengarajan, B. R. Bloom, and E. J. Rubin, “Genome-
widerequirements forMycobacteriumtuberculosisadaptation
and survival in macrophages,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 102,
no. 23, pp. 8327–8332, 2005.
[36] V. Newton, S. L. McKenna, and J. De Buck, “Presence of PPE
proteins in Mycobacterium avium subsp. paratuberculosis
isolates and their immunogenicity in cattle,” Veterinary
Microbiology, vol. 135, no. 3-4, pp. 394–400, 2009.
[37] M. K. Gupta, V. Subramanian, and J. S. Yadav, “Immuno-
proteomic identiﬁcation of secretory and subcellular protein
antigens and functional evaluation of the secretome frac-
tion of Mycobacterium immunogenum a newly recognized
species of the Mycobacterium chelonae- Mycobacterium
abscessus group,” Journal of Proteome Research,v o l .8 ,n o .5 ,
pp. 2319–2330, 2009.
[38] M. Sani, E. N. G. Houben, J. Geurtsen et al., “Direct
visualization by Cryo-EM of the mycobacterial capsular
layer: a labile structure containing ESX-1-secreted proteins,”
PLoS Pathogens, vol. 6, no. 3, Article ID e1000794, 2010.
[39] H. M˚ a l e n ,F .S .B e r v e n ,K .E .F l a d m a r k ,a n dH .G .
Wiker, “Comprehensive analysis of exported proteins from
Mycobacterium tuberculosis H37Rv,” Proteomics,v o l .7 ,n o .
10, pp. 1702–1718, 2007.
[40] H. M˚ alen, S. Pathak, T. Softeland, G. A. de Souza, and H. G.
Wiker, “Deﬁnition of novel cell envelope associated proteins
in Triton X-114 extracts of Mycobacterium tuberculosis
H37Rv,” BMC Microbiology, vol. 10, article 132, p. 132, 2010.
[41] C. Demangel,P.Brodin,P. J.Cockle et al.,“Cell envelope pro-
tein PPE68 contributes to Mycobacterium tuberculosis RD1
immunogenicity independently of a 10-kilodalton culture
ﬁltrate protein and ESAT-6,” Infection and Immunity, vol. 72,
no. 4, pp. 2170–2176, 2004.
[ 4 2 ]V .L eM o i g n e ,G .R o b r e a u ,C .B o r o t ,J .L .G u e s d o n ,a n d
W. Mahana, “Expression, immunochemical characterization
and localization of the Mycobacterium tuberculosis protein
p27,” Tuberculosis, vol. 85, no. 4, pp. 213–219, 2005.
[43] K. C. Mishra, C. De Chastellier, Y. Narayana et al., “Func-
tional role of the PE domain and immunogenicity of the
Mycobacterium tuberculosis triacylglycerol hydrolase LipY,”
Infection and Immunity, vol. 76, no. 1, pp. 127–140, 2008.
[44] A. Cascioferro, G. Delogu, M. Colone et al., “PE is a
functional domain responsible for protein translocation andClinical and Developmental Immunology 9
localization on mycobacterial cell wall,” Molecular Microbiol-
ogy, vol. 66, no. 6, pp. 1536–1547, 2007.
[ 4 5 ] S .B a n u ,N .H o n o r ´ e, B. Saint-Joanis, D. Philpott, M.
C. Pr´ evost, and S. T. Cole, “Are the PE-PGRS proteins
of Mycobacterium tuberculosis variable surface antigens?”
Molecular Microbiology, vol. 44, no. 1, pp. 9–19, 2002.
[46] G. Delogu, C. Pusceddu, A. Bua, G. Fadda, M. J. Brennan,
and S. Zanetti, “Rv1818c-encoded PE PGRS protein of
Mycobacterium tuberculosis is surface exposed and inﬂuences
bacterial cell structure,” Molecular Microbiology,v o l .5 2 ,n o .
3, pp. 725–733, 2004.
[47] S. L. Sampson, P. Lukey, R. M. Warren, P. D. Van Helden, M.
Richardson, and M. J. Everett, “Expression, characterization
andsubcellularlocalizationoftheMycobacterium tuberculosis
PPE gene Rv1917c,” Tuberculosis, vol. 81, no. 5-6, pp. 305–
317, 2001.
[48] M. J. Brennan and G. Delogu, “The PE multigene family: a
’molecular mantra’ for mycobacteria,” Trends in Microbiol-
ogy, vol. 10, no. 5, pp. 246–249, 2002.
[49] R. K. Choudhary, R. Pullakhandam, N. Z. Ehtesham, and S.
E. Hasnain, “Expression and characterization of Rv2430c, a
novel immunodominant antigen of Mycobacterium tubercu-
losis,” Protein Expression and Puriﬁcation, vol. 36, no. 2, pp.
249–253, 2004.
[50] S. Daugelat, J. Kowall, J. Mattow et al., “The RD1 proteins
of Mycobacterium tuberculosis: expression in Mycobacterium
smegmatis and biochemical characterization,” Microbes and
Infection, vol. 5, no. 12, pp. 1082–1095, 2003.
[51] S. Tundup, Y. Akhter, D. Thiagarajan, and S. E. Hasnain,
“Clusters of PE and PPE genes of Mycobacterium tuberculosis
are organized in operons: evidence that PE Rv2431c is co-
transcribed with PPE Rv2430c and their gene products
interact with each other,” FEBS Letters, vol. 580, no. 5, pp.
1285–1293, 2006.
[ 5 2 ]M .S t r o n g ,M .R .S a w a y a ,S .W a n g ,M .P h i l l i p s ,D .C a s c i o ,
and D. Eisenberg, “Toward the structural genomics of
complexes: crystal structure of a PE/PPE protein complex
fromMycobacterium tuberculosis,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 103,
no. 21, pp. 8060–8065, 2006.
[53] R.Riley,M.Pellegrini,andD.Eisenberg,“Identifyingcognate
binding pairs among a large set of paralogs: the case
of PE/PPE proteins of Mycobacterium tuberculosis,” PLoS
Computational Biology, vol. 4, no. 9, Article ID e1000174,
2008.
[54] A.M.Abdallah,N.D.L.Savage,M.VanZonetal.,“The ESX-
5 secretion system of mycobacterium marinum modulates
the macrophage response,” Journal of Immunology, vol. 181,
no. 10, pp. 7166–7175, 2008.
[55] R. Chaturvedi, K. Bansal,Y. Narayana et al., “The multifunc-
tional PE-PGRS11 protein from Mycobacterium tuberculosis
plays a role in regulating resistance to oxidative stress,”
J o u r n a lo fB i o l o g i c a lC h e m i s t r y , vol. 285, no. 40, pp. 30389–
30403, 2010.
[56] A. Singh, D. Mai, A. Kumar, and A. J. C. Steyn, “Dissecting
virulence pathways of Mycobacterium tuberculosis through
protein-protein association,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 103,
no. 30, pp. 11346–11351, 2006.
[57] J. Teutschbein, G. Schumann, U. M¨ ollmann, S. Grabley, S. T.
Cole, and T. Munder, “A protein linkage map of the ESAT-
6 secretion system 1 (ESX-1) of Mycobacterium tuberculosis,”
Microbiological Research, vol. 164, no. 3, pp. 253–259, 2009.
[58] P. Brodin, I. Rosenkrands, P. Andersen, S. T. Cole, and R.
Brosch, “ESAT-6 proteins: protective antigens and virulence
factors?” Trends in Microbiology, vol.12, no. 11, pp. 500–508,
2004.
[59] K. N. Balaji, G. Goyal, Y. Narayana, M. Srinivas, R.
Chaturvedi, and S. Mohammad, “Apoptosis triggered by
Rv1818c, a PE family gene from Mycobacterium tuberculosis
is regulated by mitochondrial intermediates in T cells,”
Microbes and Infection, vol. 9, no. 3, pp. 271–281, 2007.
[60] L. Ramakrishnan, N. A. Federspiel, and S. Falkow,
“Granuloma-speciﬁc expression ofMycobacterium virulence
proteins from the glycine-rich PE-PGRS family,” Science,v o l .
288, no. 5470, pp. 1436–1439, 2000.
[ 6 1 ]S .B a s u ,S .K .P a t h a k ,A .B a n e r j e ee ta l . ,“ E x e c u t i o no f
macrophage apoptosis by PE PGRS33 of Mycobacterium
tuberculosis is mediated by toll-like receptor 2-dependent
release of tumor necrosis factor-α,” Journal of Biological
Chemistry, vol. 282, no. 2, pp. 1039–1050, 2007.
[62] V. Dheenadhayalan, G. Delogu, and M. J. Brennan, “Expres-
sion of the PE P G R S3 3p r o t e i ni nM y c o b a c t e r i u ms m e g m a -
tis triggers necrosis in macrophages and enhanced mycobac-
terial survival,” Microbes and Infection, vol. 8, no. 1, pp. 262–
272, 2006.
[ 6 3 ] K .B a n s a l ,S .R .E l l u r u ,Y .N a r a y a n ae ta l . ,“ P EPGRS antigens
of Mycobacterium tuberculosis induce maturation and activa-
tion of human dendritic cells,” Journal of Immunology,v o l .
184, no. 7, pp. 3495–3504, 2010.
[ 6 4 ]S .N a i r ,P .A .R a m a s w a m y ,S .G h o s he ta l . ,“ T h eP P E 1 8o f
Mycobacterium tuberculosis interacts with TLR2 andactivates
IL-10 induction in macrophage,”Journal of Immunology,v o l .
183, no. 10, pp. 6269–6281, 2009.
[65] K.Bansal,A.Y .Sinha,D .S.Ghorpadeetal.,“ Sr chomology3-
interactingdomainofRv1917cofMycobacterium tuberculosis
induces selective maturation of human dendritic cells by
regulating PI3K-MAPK-NF-κB signaling and drives Th2
immune responses,” J o u r n a lo fB i o l o g i c a lC h e m i s t r y , vol. 285,
no. 47, pp. 36511–36522, 2010.
[66] M. J. Brennan, G. Delogu, Y. Chen et al., “Evidence that
mycobacterial PE PGRS proteins are cell surface constituents
that inﬂuence interactions with other cells,” Infection and
Immunity, vol. 69, no. 12, pp. 7326–7333, 2001.
[67] P. K. Mehta,A. K. Pandey, S. Subbian et al., “Identiﬁcationof
Mycobacterium marinum macrophage infection mutants,”
Microbial Pathogenesis,vol. 40, no. 4, pp. 139–151, 2006.
[68] P. P. Singh, M. Parra, N. Cadieux, and M. J. Brennan, “A
comparative study of host response to three Mycobacterium
tuberculosis PE PGRS proteins,” Microbiology, vol. 154, no.
11, pp. 3469–3479, 2008.
[69] S. Jha, L. Danelishvili, D. Wagner et al., “Virulence-related
Mycobacterium avium MAV 2928 gene is associated with
vacuole remodeling in macrophages,” BMC Microbiology,
vol. 10, article 100, p. 100, 2010.
[70] Y .Li,E.Miltner ,M.W u,M.P etr ofsky ,andL.E.Bermudez,“ A
Mycobacterium aviumPPEgene isassociatedwith theability
of the bacterium to grow in macrophages and virulence in
mice,” Cellular Microbiology, vol. 7, no. 4, pp. 539–548, 2005.
[71] G. R. Stewart, J. Patel, B. D. Robertson, A. Rae, and D.
B. Young, “Mycobacterial mutants with defective control
of phagosomal acidiﬁcation,” PLoS Pathogens,v o l .1 ,n o .3 ,
article e33, pp. 0269–0278, 2005.
[72] P. Brodin, Y. Poquet, F. Levillain et al., “High content
phenotypic cell-based visual screen identiﬁes Mycobacterium
tuberculosis acyltrehalose-containing glycolipids involved in
phagosomeremodeling,” PLoS Pathogens, vol. 6, no. 9, 2010.10 Clinical and Developmental Immunology
[73] C. Deb, J. Daniel, T. D. Sirakova, B. Abomoelak, V. S. Dubey,
and P. E. Kolattukudy, “A novel lipase belonging to the
hormone-sensitive lipase family induced under starvation to
utilize stored triacylglycerol in Mycobacterium tuberculosis,”
J o u r n a lo fB i o l o g i c a lC h e m i s t r y , vol. 281, no. 7, pp. 3866–
3875, 2006.
[74] K. W. Koh, N. Lehming, and G. T. Seah, “Degradation-
resistant protein domains limit host cell processing and
immune detection of mycobacteria,” Molecular Immunology,
vol. 46, no. 7, pp. 1312–1318, 2009.
[75] C. M. Bosio, D. Gardner, and K. L. Elkins, “Infection
of B cell-deﬁcient mice with CDC 1551, a clinical isolate
of Mycobacterium tuberculosis: delay in dissemination and
development of lung pathology,” Journal of Immunology,v o l .
164, no. 12, pp. 6417–6425, 2000.
[76] P. J. Maglione, J. Xu, and J. Chan, “B cells moderate inﬂam-
matory progression and enhance bacterial containment
uponpulmonarychallengewithMycobacteriumtuberculosis,”
Journal of Immunology,vol.178,no.11,pp. 7222–7234,2007.
[ 7 7 ] F .E .L u n d ,M .H o l l i ﬁ e l d ,K .S c h u e r ,J .L .L i n e s ,T .D .R a n d a l l ,
and B. A. Garvy, “B cells are required for generation of
protective eﬀector and memory CD4 cells in response to
Pneumocystis lung infection,” Journal of Immunology,v o l .
176, no. 10, pp. 6147–6154, 2006.
[78] H. Shen, J. K. Whitmire, X. Fan, D. J. Shedlock, S. M.
Kaech, and R. Ahmed, “A speciﬁc role for B cells in the
generation of CD8 T cell memory by recombinant Listeria
monocytogenes,” Journal of Immunology, vol. 170, no. 3, pp.
1443–1451, 2003.
[79] M. C. Tsai, S. Chakravarty, G. Zhu et al., “Characterization
of the tuberculous granuloma in murine and human lungs:
cellular composition and relative tissue oxygen tension,”
Cellular Microbiology, vol. 8, no. 2, pp. 218–232, 2006.
[80] G. Delogu and M. J. Brennan, “Comparative immune
response to PE and PE PGRS antigens of Mycobacterium
tuberculosis,” InfectionandImmunity,vol.69,no.9,pp.5606–
5611, 2001.
[81] P. Chakhaiyar, Y. Nagalakshmi, B. Aruna, K. J. R. Murthy, V.
M. Katoch, and S. E. Hasnain, “Regions of high antigenicity
within the hypothetical PPE major polymorphic tandem
repeat open-reading frame, Rv2608, show a diﬀerential
humoral response and a low T cell response in various
categories of patients with tuberculosis,” Journal of Infectious
Diseases,vol. 190, no. 7, pp. 1237–1244, 2004.
[82] W. K. Kah, E. S. Shu, and T. S. Geok, “Strong antibody
responses to Mycobacterium tuberculosis PE-PGRS62 protein
are associated with latent and active tuberculosis,” Infection
and Immunity, vol. 77, no. 8, pp. 3337–3343, 2009.
[ 8 3 ]A .M .C a r u s o ,N .S e r b i n a ,E .K l e i n ,K .T r i e b o l d ,B .R .
Bloom, and J. L. Flynn, “Mice deﬁcient in CD4 T cells have
only transiently diminished levels of IFN-γ,y e ts u c c u m bt o
tuberculosis,” Journal of Immunology, vol. 162, no. 9, pp.
5407–5416, 1999.
[84] J. L. Flynn, M. M. Goldstein, K. J. Triebold, B. Koller, and
B. R. Bloom, “Major histocompatibility complex class I-
restricted T cells are required forresistance to Mycobacterium
tuberculosis infection,”Proceedings of theNational Academyof
Sciences of the United States of America, vol. 89, no. 24, pp.
12013–12017, 1992.
[ 8 5 ]D .C .D i l l o n ,M .R .A l d e r s o n ,C .H .D a ye ta l . ,“ M o l e c u l a r
characterization and human T-cell responses to a member
of a novel Mycobacterium tuberculosis mtb39 gene family,”
Infection and Immunity, vol. 67, no. 6, pp. 2941–2950, 1999.
[86] I. Comas, J. Chakravartti, P. M. Small et al., “Human T
cell epitopes of Mycobacterium tuberculosis are evolutionarily
hyperconserved,” Nature Genetics,vol.42,no.6,pp.498–503,
2010.
[87] A. L. Graham, J. E. Allen, and A. F. Read, “Evolutionary
causes and consequences of immunopathology,” Annual
ReviewofEcology,Evolution,andSystematics,vol.36,pp.373–
397, 2005.
[88] R. Nagata, Y. Muneta, K. Yoshihara, Y. Yokomizo, and Y.
Mori, “Expression cloning of gamma interferon-inducing
antigens of Mycobacterium avium subsp. paratuberculosis,”
Infection and Immunity, vol. 73, no. 6, pp. 3778–3782, 2005.
[ 8 9 ]M .P a r r a ,N .C a d i e u x ,T .P i c k e t t ,V .D h e e n a d h a y a l a n ,a n d
M. J. Brennan, “A PE protein expressed by Mycobacterium
avium is an eﬀective T-cell immunogen,” Infection and
Immunity, vol. 74, no. 1, pp. 786–789, 2006.
[90] P. J. Cockle, S. V. Gordon, A. Lalvani, B. M. Buddle, R.
G. Hewinson, and H. M. Vordermeier, “Identiﬁcation of
novel Mycobacterium tuberculosis antigens with potential
as diagnostic reagents or subunit vaccine candidates by
comparative genomics,” Infection and Immunity,v o l .7 0 ,n o .
12, pp. 6996–7003, 2002.
[91] G. C. Ireton, R. Greenwald, H. Liang, J. Esfandiari, K. P.
Lyashchenko, and S. G. Reed, “Identiﬁcation of Mycobac-
terium tuberculosis antigens of high serodiagnostic value,”
Clinical and Vaccine Immunology, vol. 17, no. 10, pp. 1539–
1547, 2010.
[92] N.Khan,K.Alam,S.N air ,V .L.V alluri,K.J.R.M urthy ,andS.
Mukhopadhyay, “Association of strong immune responses to
PPE protein Rv1168c with active tuberculosis,” Clinical and
Vaccine Immunology, vol. 15, no. 6, pp. 974–980, 2008.
[93] K .K .Singh,Y .D ong,S.A .P at ib and la,D .N .M c M u rra y ,V .K .
Arora, and S. Laal, “Immunogenicity of the Mycobacterium
tuberculosis PPE55 (Rv3347c) protein during incipient and
clinical tuberculosis,” Infection and Immunity, vol. 73, no. 8,
pp. 5004–5014, 2005.
[94] K. K. Singh,X. Zhang, A. S. Patibandla, P. Chien, and S. Laal,
“Antigens of Mycobacterium tuberculosis expressed during
preclinical tuberculosis: serological immunodominance of
proteins with repetitive amino acid sequences,” Infection and
Immunity, vol. 69, no. 6, pp. 4185–4191, 2001.
[95] H. Zhang, J. Wang, J. Lei et al., “PPE protein (Rv3425)
from DNA segment RD11 of Mycobacterium tuberculosis:
a potential B-cell antigen used for serological diagnosis to
distinguish vaccinated controls from tuberculosis patients,”
Clinical Microbiology and Infection, vol. 13, no. 2, pp. 139–
145, 2007.
[ 9 6 ]K .W e l d i n g h ,I .R o s e n k r a n d s ,L .M .O k k e l s ,T .M .D o h e r t y ,
and P. Andersen, “Assessing the serodiagnostic potential of
35 Mycobacterium tuberculosis proteins and identiﬁcation of
four novel serological antigens,” Journal of Clinical Microbi-
ology, vol. 43, no. 1, pp. 57–65, 2005.
[97] S. Bertholet, G. C. Ireton, M. Kahn et al., “Identiﬁcation
of human T cell antigens for the development of vaccines
against Mycobacterium tuberculosis,” Journal of Immunology,
vol. 181, no. 11, pp. 7948–7957, 2008.
[98] J. Campuzano, D. Aguilar, K. Arriaga et al., “The PGRS
domain of Mycobacterium tuberculosis.P EPGRS Rv1759c
antigen is an eﬃcient subunit vaccine to prevent reactivation
in a murine model of chronic tuberculosis,” Vaccine, vol. 25,
no. 18, pp. 3722–3729, 2007.
[ 9 9 ]M .R o m a n o ,L .R i n d i ,H .K o r fe ta l . ,“ I m m u n o g e n i c i t ya n d
protective eﬃcacyoftuberculosissubunitvaccinesexpressingClinical and Developmental Immunology 11
PPE44 (Rv2770c),” Vaccine, vol. 26, no. 48, pp. 6053–6063,
2008.
[100] Y. A. W. Skeiky, P. J. Ovendale, S. Jen et al., “T cell expression
cloning of a Mycobacterium tuberculosis gene encoding a
protective antigen associated with the early control of
infection,” Journal of Immunology, vol.165, no. 12, pp. 7140–
7149, 2000.
[101] J. Vipond, R. Vipond, E. Allen-Vercoe et al., “Selection of
novel TB vaccine candidates and their evaluation as DNA
vaccines against aerosol challenge,” Vaccine, vol. 24, no. 37–
39, pp. 6340–6350, 2006.
[102] J. L. Wang, YA. Q. Qie, B. D. Zhu et al., “Evaluation of
a recombinant BCG expressing antigen Ag85B and PPE
protein Rv3425 from DNA segment RD11 of Mycobacterium
tuberculosis in C57BL/6 mice,” Medical Microbiology and
Immunology, vol. 198, no. 1, pp. 5–11, 2009.
[103] S. G. Reed, R. N. Coler, W. Dalemans et al., “Deﬁned tuber-
culosis vaccine, Mtb72F/AS02A, evidence of protection in
cynomolgus monkeys,” Proceedings of the National Academy
of Sciences of the United States of America, vol. 106, no. 7, pp.
2301–2306, 2009.
[104] L.Tsenova,R. Harbacheuski,A.L.Moreira etal.,“Evaluation
of the Mtb72F polyprotein vaccine in a rabbit model of
tuberculous meningitis,” Infection and Immunity, vol. 74, no.
4, pp. 2392–2401, 2006.
[105] I. Leroux-Roels, G. Leroux-Roels, O. Ofori-Anyinam et
al., “Evaluation of the safety and immunogenicity of two
antigen concentrations of the Mtb72F/AS02A candidate
tuberculosis vaccine in puriﬁed protein derivative-negative
adults,” Clinical and Vaccine Immunology, vol. 17, no. 11, pp.
1763–1771, 2010.
[106] K. Von Eschen, R. Morrison, M. Braun et al., “The can-
didate tuberculosis vaccine Mtb72F/AS02A: tolerability and
immunogenicity in humans,” Human Vaccines,v o l .5 ,n o .7 ,
pp. 475–482, 2009.
[107] S. L. Baldwin, S. Bertholet, M. Kahn et al., “Intradermal
immunization improves protective eﬃcacy of a novel TB
vaccine candidate,” Vaccine, vol. 27, no. 23, pp. 3063–3071,
2009.
[108] S. Bertholet, G. C. Ireton, D. J. Ordway et al., “A deﬁned
tuberculosis vaccine candidate boosts BCG and protects
against multidrug-resistant Mycobacterium tuberculosis,” Sci-
ence Translational Medicine, vol. 2, no. 53, Article ID 53ra74,
2010.
[109] H.-W. Mittr¨ ucker, U. Steinhoﬀ,A .K ¨ ohler et al., “Poor cor-
relation between BCG vaccination-induced T cell responses
and protection against tuberculosis,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 104, no. 30, pp. 12434–12439, 2007.
[110] A. Lalvani and K. A. Millington, “T cells and tuberculosis:
beyond interferon-γ,” Journal of Infectious Diseases, vol. 197,
no. 7, pp. 941–943, 2008.
[111] L. M. Connor, M. C. Harvie, F. J. Rich et al., “A key
role for lung-resident memory lymphocytes in protective
immune responses after BCG vaccination,” European Journal
of Immunology, vol. 40, no. 9, pp. 2482–2492, 2010.
[112] M. G. Chaitra, S. Hariharaputran, N. R. Chandra, M. S.
Shaila, and R. Nayak, “Deﬁning putative T cell epitopes
from PE and PPE families of proteins of Mycobacterium
tuberculosis with vaccine potential,” Vaccine, vol. 23, no. 10,
pp. 1265–1272, 2005.
[113] A. M. Hebert, S. Talarico, D. Yang et al., “DNA polymor-
phisms in the pepA and PPE18 genes among clinical strains
of Mycobacterium tuberculosis: implications for vaccine eﬃ-
cacy,” Infection and Immunity,vol. 75,no.12, pp. 5798–5805,
2007.
[114] L. A. McNamara, Y. He, and Z. Yang, “Using epitope
predictions to evaluate eﬃcacy and population coverage of
the Mtb72f vaccine for tuberculosis,” BMC Immunology,v o l .
11, article 18, 2010.